Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report Q3 2021 - Ayima Grou AB

Q3 - Jul to Sep 2021 · Total Revenue amounted to 42.9 MSEK (30.4), an increase of 41% from the corresponding period in 2020 · Gross Profit amounted to 21.9 MSEK (19.0), an increase of 15% from the corresponding period in 2020 · Operating costs amounted to 17.2 MSEK (17.7), a reduction of 3% from the corresponding period last year · A positive EBITDA result of 4.7 MSEK (1.3), a 258% increase from the corresponding period in 2020 · EBITDA margin increased to 11% (4%) · Net Profit after tax for the period was 1.5 MSEK (-1.5), an increase of 3.0 MSEK from the corresponding

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

Lu AF82422 represents a novel approach for potential treatment of multiple system atrophy (MSA), which currently represents a high and urgent unmet medical need.H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is ready to initiate the AMULET study, which is designed to confirm the potential of Lu AF82422 as a treatment to slow the rate of disease progression of multiple system atrophy (MSA). MSA is a serious, rare, sporadic, and rapidly deteriorating neurodegenerative disease that gradually damages brain cells. Current therapeutic intervention is

Three-way cooperation for maximized data center security

Core Data Centres, iLOQ and the system integrator successfully worked together to formulate a locking system that could ensure smooth and secure access to servers in the Canadian data center. Core Data Centres Inc. owns and operates several state-of-the-art data centers in Canada. With the company providing solutions ranging from cloud and information technology services to managed services and colocation, maintaining high levels of security is vital. Rack space is leased to many customers meaning there is a constant flow of people needing to access their own servers. Any

BioStock: Pre-clinical data indicates wider use for Cyxone’s T20K in MS

Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner, the Medical University of Vienna, presented pre-clinical data supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist, the combination having potential expanded therapeutic utility. BioStock reached out to COO Carl-Magnus Högerkorp for a comment.Read the interview with Cyxone's COO Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2021/11/pre-clinical-data-indicates-wider-

Great interest from the capital market as Greenfood issues bond linked to the Group's sustainability work

Greenfood AB (publ) has successfully issued a four-year sustainability-linked bond for SEK 1,050 million. The bond is linked to Greenfood's Sustainability Framework’s targets. The Framework has been reviewed by an independent second opinion provider and has received the highest possible rating. After significant interest from both leading Nordic and European investors, the bond was quickly oversubscribed. To fund growth and investment in developing a sustainable business, Greenfood AB (publ) has successfully issued a sustainability-linked bond for SEK 1,050 million. The bond was quickly

QLIFE HOLDING AB INTERIM REPORT Q3, 2021

Covid-19 test sales moving to Egoo platformFINANCIAL SUMMARY – THIRD QUARTER 2021 · Revenue in the period amounted to kSEK 5,871 (5,062). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing. · EBITDA for the period amounted to kSEK -12,229 (-5,043), and net loss kSEK -14,998 (-2,757). · The total cash flow in the third quarter amounted to kSEK -25,580 (-11,714). · Earnings per share before/after dilution for the third quarter amounted to SEK -1.13 (-0.25), calculated on weighted average number of

DBP International AB has together with Bio Vitos Medical Ltd signed an agreement on scientific, technical and sales collaboration with Belarusian Academpharm

Double Bond Pharmaceutical International AB (publ) (“DBP”) has signed a 3-way agreement with Bio Vitos Medical Ltd (“Bio Vitos”) and Academpharm (Republic of Belarus) concerning a technical and scientific collaboration. The purpose of the agreement between Academpharm and Bio Vitos is to get access to its products on the markets in the Eurasian Economic Union (EaEU). Bio Vitos has a line of more than 40 Omega 3 products from North Norway, containing vitamins, minerals, iron succinate etc. The Bio Vitos agreement with Academpharm, gives access to the countries: Belarus, Russia,

PANTAX study read-out postponed

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the timeline for read-out of the dose-finding clinical Phase Ib study PANTAX will be extended, and read-out is now expected in Q2-Q3 2022. The reasons are challenging patient recruitment and a staggered study design. Disregarding this postponement, the study is performing as well as the Company could have hoped for.In the PANTAX study, Scandion Oncology enrolls patients with unresectable or metastatic pancreatic cancer. The recruitment rate of patients in this very fragile patient population has been lower than

Implantica takes a big step forward in its RefluxStop™ U.S. approval process discussions with FDA

Implantica AG (publ) today announces feedback from its third pre-submission meeting with the U.S. Food and Drug Administration (FDA) for the approval of RefluxStop™. FDA indicated its willingness to accept a Premarket Approval (PMA) submission for review based solely on the existing long-term European data for RefluxStop™, which if approved, would allow for U.S. market entry without a premarket U.S. clinical trial.Implantica received helpful feedback from the FDA in its recent supplemental pre-submission meeting where the regulatory pathway of RefluxStop™ was discussed. Due to the favorable

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 5th November 2021, acquired interests in shares of Otello Corporation ASA.The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,177,798 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Fellow Finance's payment methods are now in use across thousands online stores

FELLOW FINANCE PLC PRESS RELEASE 8.11.2021 AT 9:10 AMFellow Finance is the first crowdfunding and peer-to-peer lending platform in Finland that expands its product range to include “buy now, pay later” online store payment method Fellow Finance’s advanced e-commerce payment method, Fellow Lasku, is now available across thousands Finnish online stores using the Visma Pay Online Payment Service. With Fellow Lasku, a consumer has an option to pay an e-commerce purchase either with a 30-day interest-free invoice or in flexible monthly installments. In addition, Fellow Finance has entered

Bambuser AB Publishes Interim Report for Q3 2021

Bambuser presents yet another record quarter with strong growth. During Q3, the Monthly Recurring Revenue (MRR) increased by + 213%, while the Total Contract Value (TCV) grew by +1043 compared to the same period last year. The interim report has now been published and can be found at ir.bambuser.com.Third quarter (July – September 2021) · Total revenue amounted to 49.0 MSEK (12.2) · Net Sales amounted to 41.5 MSEK (10.1), an increase of +311% YoY · Adjusted EBITDA amounted to –19.6 MSEK (–7.9) · EBIT amounted to –59.9 MSEK (-9.2) · Net income amounted to –59.8 MSEK (–9.2)

Agnafit Bidco further extends the acceptance period for the public offer to the shareholders of Sobi

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in

Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO

Lund, Sweden November 8, 2021 Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary Shares (“ADSs”) in the United States (a “U.S. IPO”) representing Hansa’s ordinary shares and listing of ADSs on the Nasdaq Stock Market (“Nasdaq”). The number of ADSs that may be offered, the number of underlying

Biomedical Bonding AB has been granted a patent in China for its novel primer technology

Press release: Biomedical Bonding AB's novel primer formulation has been granted a patent in China. The primer is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration treatments.Biomedical Bonding AB has secured a unique primer formulation patent for use together with its resin-based composite technology, a first of a kind universal fracture fixation solution that is going to be revolutionary in the world of surgery and treatments for fractures. The recently granted

Nightingale Health Plc – Managers’ transactions – Timo Soininen

Managers' Transactions 8 November 2021 at 9:00 a.m. (EET) ____________________________________________ Person subject to the notification requirement Name: Soininen, Timo Position: Member of the Board/Deputy member Issuer: Nightingale Health Oyj LEI: 743700WUIPC24LVMLO66 Notification type: INITIAL NOTIFICATION Reference number: 743700WUIPC24LVMLO66_20210916201315_2 ____________________________________________ Transaction date: 2021-11-05 Venue: FIRST NORTH FINLAND (FNFI) Instrument type: SHARE ISIN: FI4000490875 Nature of the transaction:

Moberg Pharma enters into collaboration with Allderma for launch in Scandinavia

Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden, Norway and Denmark. Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox[®], Moberg Pharma’s first-generation nail fungus product.In the collaboration, Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delivery of the product. The agreement also includes co-financing of marketing activities and market-

New data published on ABBV-0805 in Neurobiology of Disease

Stockholm, November 8, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805. The publication includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates.The article entitled ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson’s disease focuses on the preclinical findings that continue to support

Calmark Sweden AB (publ) publishes information memorandum in view of rights issue

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today that the information memorandum in view of the Company's previously announced rights issue (“the Rights Issue”) has been approved by Spotlight Stock Market. The information memorandum and other relevant information will be made available on the Company’s website, www.calmark.se, on Hagberg & Aneborn Fondkommission AB’s website, www.hagberganeborn, and on Spotlight Stock Market’s website, www.spotlightstockmarket.com.The rights issue in brief On 22 October 2021, the Board of Directors resolved,

Coor acquires Inspira

Coor today signed an agreement relating to the acquisition of Inspira, a well-run family business that delivers workplace services, mainly focused on cleaning, for a large number of customers in central Sweden. The acquisition increases Coor’s geographical coverage in central Sweden and generates significant synergies.Inspira has 1,400 employees and annual sales of some SEK 700 M. The purchase consideration (on a cash and debt free basis) amounts to SEK 380 M and corresponds to an EV/EBITA multiple of approximately 8x in relation to current EBITA, and close to 6x when expected synergies are

Change in Optomed’s holding of treasury

Optomed Plc Stock Exchange Release 8 November 2021 at 9.00, Helsinki Change in Optomed’s holding of treasury A total of 42,450 of shares have been subscribed for under the Company’s stock option plans 2015, 2017, 2017B and 2018C and Optomed has used treasury shares for the share subscriptions. The subscribed shares have been delivered to the subscribers on 5 November 2021. The total amount of treasury shares is now 421,517. Optomed Plc Further enquiries Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com   Optomed in Brief  Optomed is a Finnish medical

Aker Solutions Wins Umbilicals Contract for Jansz-Io Compression Project

November 8, 2021 – Aker Solutions has been awarded a sizeable[1] contract from Chevron Australia Pty Ltd to provide the dynamic subsea umbilicals for the Jansz-Io subsea gas compression development, offshore Australia.The contract includes the delivery of engineering, design and manufacturing of a total of about 70 kilometers of dynamic subsea umbilicals. The scope of work includes three subsea compressor umbilicals, two subsea pump umbilicals, as well as ancillary equipment and spares. The umbilicals will provide power from the platform to the subsea compressor and pump modules. "We are

There are no items matching the current filter
There are no more items matching the current filter
Back to top